MeningomyeloceleNCT04027374
Stress-associated Epigenetic Alterations in Newborns After Fetal Surgery
An observational study of Meningomyelocele, run by University Children's Hospital, Zurich at 1 site in Switzerland.
Trial summary
Open spina bifida or myelomeningocele (MMC) is a devastating congenital defect of the central nervous system for which there is no cure. The etiology of MMC remains poorly understood. Read more about this study
- Who is it for?
- Ages 2 days to 3 monthsHealthy volunteers can take part
- Conditions the study is for
- Meningomyelocele
- What is being tested?
- Fetal surgery for MMC repair
- Type of treatment
- Surgery or procedure
- How many people
- 70 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jul 2019to 31 Aug 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 days to 3 months
- All sexes
- Healthy volunteers accepted
- Child
Study population: The study will include newborns after fetal surgery for MMC at the University Hospital Zurich and two control groups. One including healthy newborns and another including newborns after prenatal exposure to synthetic glucocorticoids (sGC) in pregnancy. Each group shall include n=30 newborns (i.e. total number of study participants: n=90). In the following paragraph you can find a detailed description of the groups as well as the inclusion and exclusion criteria for all groups.
Who may be able to join
- Group 1: Newborns after successful fetal surgery for MMC, delivered by ECS (elective c-section) at weeks 350 - 370.
- Group 2: Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by ECS between 350 - 400 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure.
- Group 3: Healthy newborns, uncomplicated pregnancy, delivered at term by ECS between 360 - 390 weeks (healthy controls). Matched for child sex with group 1.
Who cannot join
- Multiple pregnancies
- Apgar 5 min <=7, or significant postpartal health problems such as respiratory distress syndrome
- ph<7.15
- General anaesthesia for ECS
- Insufficient knowledge of German or English by the mother
- Mother exposed to traumatic stress during pregnancy (other than fetal surgery)
- Non-Caucasian origin
- Egg donation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Epigenetic Alterations in Stress Regulation Genes Among Newborns After Fetal Surgery for Myelomeningocele Repair: An Exploratory Study
Open spina bifida or myelomeningocele (MMC) is a devastating congenital defect of the central nervous system for which there is no cure. The etiology of MMC remains poorly understood. Primary failure of neural tube closure at the caudal neuropore in the embryonic period results in exposure of the developing spinal cord to the uterine environment. Without protective tissue coverage, secondary destruction of the exposed neural tissue by trauma or amniotic fluid may occur throughout gestation. In order to protect the spinal cord from this secondary destruction, a fetal surgical repair can be performed between gestational weeks 20 and 26.
From a psychological point of view fetal repair of MMC constitutes a highly stressful event both for the mother and the fetus. To date, however, stress of mothers and children in case of prenatal surgery for MMC repair has never been studied. It is therefore unclear, if and to what extend the procedure and its consequences are associated with stress, and if there are short- or longer-term consequences.
Read more
The aims of this study are threefold:
- Do newborns after fetal surgery for MMC show epigenetic alterations in genes that are involved in stress regulation?
- With which medical and psychosocial variables are epigenetic alterations associated?
- At age 3 months, do infants after fetal surgery have a more difficult temperament compared to controls?
Read the detailed description
BACKGROUND AND AIMS:
Open spina bifida or myelomeningocele (MMC) is a devastating congenital defect of the central nervous system for which there is no cure. The etiology of MMC remains poorly understood. Primary failure of neural tube closure at the caudal neuropore in the embryonic period results in exposure of the developing spinal cord to the uterine environment. Without protective tissue coverage, secondary destruction of the exposed neural tissue by trauma or amniotic fluid may occur throughout gestation. In order to protect the spinal cord from this secondary destruction, a fetal surgical repair can be performed between gestational weeks 20 and 26.
From a psychological point of view fetal repair of MMC constitutes a highly stressful event both for the mother and the fetus. To date, however, stress of mothers and children in case of prenatal surgery for MMC repair has never been studied. It is therefore unclear, if and to what extend the procedure and its consequences are associated with stress, and if there are short- or longer-term consequences.
The aims of this study are threefold:
- Do newborns after fetal surgery for MMC show epigenetic alterations in genes that are involved in stress regulation?
- With which medical and psychosocial variables are epigenetic alterations associated?
- At age 3 months, do infants after fetal surgery have a more difficult temperament compared to controls?
METHODS:
Sample: The study will include newborns after fetal surgery for MMC at the University Hospital Zurich and two control groups. One including healthy newborns and another including newborns after prenatal exposure to synthetic glucocorticoids (sGC) in pregnancy. Each group shall include n=30 newborns (i.e. total number of study participants: n=90).
Recruitment and Procedures: Recruitment will take place at the University Children's Hospital and the University Hospital Zürich and will be continued until the required sample size is reached. For every MMC-patient, secondary recruitment of a control child for group 2 and 3 will be performed (matched for child sex). Parents of all study groups will be approached by the responsible study staff after checking for inclusion and exclusion criteria. They will be informed orally about the study and the study information letter (see encl.) will be provided. Parents will be contacted again after >24h face to face or by phone by study staff to answer any questions, if necessary. If the parents agree to participate in the study, they will provide the signed written informed consent form (see encl.). After inclusion in the study, the parents will be contacted again in hospital by study staff around 24-36 hours after birth to re-explain the collection of the saliva samples. The saliva samples will then be collected between 24 and 72h postpartum. Six weeks and 3 months post-partum, the parents will receive the study questionnaires by mail and they will be asked to complete and return them within 1 week. If the questionnaires are not received after 10 days, study staff will contact the parents by phone for a gentle reminder. Parents are not financially compensated for taking part in the study.
Collected data:
-) DNA and RNA sample collection from the child will take place between 24 and 72 hours of life during hospitalization by trained research project staff. In order to obtain DNA and RNA, saliva will be collected using special sponge devices designed for use with infants who cannot spit independently.
For DNA, 2x ORAcollect for pediatrics (OC-175; DNA Genotek Inc) will be used to collect saliva in order to obtain enough DNA sample.
For RNA, 2x saliva collection devices for pediatrics (CP-190; DNA Genotek Inc) will be used to collect saliva in order to obtain enough RNA sample from the newborns.
- Medical data: a) Child: Gestational age at birth; gender; birth length and percentile; birth weight and percentile; head circumference at birth and percentile; Apgar score; umbilical artery ph and lactate; meconium-stained amniotic fluid; Gestational age at fetal surgery; time and length of fetal surgery; positioning of the fetus necessary; transfer to neonatology (group 2 and 3). b) Mother: Maternal age; parity; gestational age at glucocorticoid treatment; treatment of preterm labour; medications during pregnancy; surgery and perinatal variables; history in terms of smoking, alcohol, nicotine, marihuana, other illicit drugs; Indication for ECS (group 2 and 3).
- Psychosocial data: The following variables shall be assessed from mothers by standardized and validated questionnaires: country of birth (parents, grandparents); Socio-economic status, maternal and parental education; current job situation (no, part-time, full-time); maternal and paternal trauma history (Childhood Trauma Questionnaire - Short Form from Bernstein \& Fink, 1998; Karos et al. 2014); significant life events during the pregnancy (Life Event Scale from Landolt \& Vollrath, 1998); maternal and paternal subjective stress during pregnancy (Perceived Stress Scale PSS-10 from Cohen, Kamarck, \& Mermelstein (1983) and Klein et al. (2016); maternal and paternal mental health both retrospectively during pregnancy and currently at the assessment points after birth: anxiety and depression by means of two modules of the Patient Health Questionnaire PHQ from Spitzer, Kroenke, \& Williams (1999); posttraumatic stress disorder by means of the International Trauma Questionnaire ITQ (Cloitre et al., 2018) and the infant's temperament by means of the Infant Behaviour Questionnaire IBQ - Very Short Form by Rothbart (1981). All measures are standardized and available in validated German versions.
Statistical Analyses: Aim 1 will be examined with ANCOVAs to compare total methylation / gene-expression (mRNA level) for the studied gene regions across the 3 groups. The correlation between methylation levels and gene-expression will be investigated, expecting that hypermethylation induces reduced gene-expression and vice versa.
Aim 2 will be examined by (partial) correlational analyses between predictor variables and total methylation. If requirements are met, multivariate analyses will be performed.
Aim 3 will be examined with ANCOVAs comparing IBQ-scores across the three groups.
Data will not be transformed before analysis. If the data doesn't meet the requirements for the selected statistical tests, then modified tests (e.g. one-way testing) or appropriate tests (e.g. non-parametric methods) will be used.
Statistical analysis will be performed either with the program Statistical Package for Social Sciences (SPSS, Version 25) or the statistical program R. Statistical significance will be set to a significance level of α= <.05.
Sample size: According to a power-analysis calculation with the program G*Power 3.1 (Faul, Erdfelder, Buchner \& Lang, 2009), the required sample size for an ANCOVA with 3 groups, an effect size of d=0.4 (small effect) and a power of .90 is n=84.
- Conditions
- Meningomyelocele
- Being tested
- Fetal surgery for MMC repair
- Medical subject headings
- Meningomyelocele
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fetal surgery for MMC repairProcedure or surgery
Fetal surgery for MMC repair
| Study group | Role | What they receive |
|---|---|---|
| Fetal surgery group | Newborns after successful fetal surgery for MMC, delivered by elective c-section at weeks 35;0 - 37;0. Receives: Procedure: Fetal surgery for MMC repair | |
| Glucocorticoid control group | Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by elective c-section between 35;0 - 40;0 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure. | |
| Healthy controls | Healthy newborns, uncomplicated pregnancy, delivered at term by elective c-section between 36;0 - 39;0 weeks. Matched for child sex with group 1. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Methylation status at NRC3C1 and the FKBP5 gene
Saliva DNA will be isolated using prepIT.L2P following manufacturer's protocol (PT-L2P; DNA Genotek Inc.). DNA concentration, A260/A280 and A260/A230 ratios for integrity and quality will be measured using the NanoDrop spectrophotometer (ThermoFisher, Switzerland).
DNA methylation specific analysis for each selected gene (NR3C1 and FKBP5) will be conducted using the EpiTect Methyl II PCR assays (Qiagen) following the manufacturer's protocol.
Measured: Day 2 - Day 3
Secondary outcomes (1)
Patient Health Questionnaire (PHQ)
Maternal and paternal mental health will be assessed by the Patient Health Questionnaire (PHQ) bei Spitzer et al., 1999. The questionnaire consists of 9 items with a Likert Scale from 0-3. The sum score (range 0-27) will be used. Higher scores represent more mental health problems.
Measured: Week 6 and month 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2019
- Study start1 Jul 2019
- Primary completion30 Apr 2023
- Study completion31 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MeningomyeloceleStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Children's Hospital, Zurich
- Sponsor type
- University, hospital or other
- Collaborators
- University of Zurich, Psychiatric University Hospital, Zurich
- Responsible party
- Sponsor
- Investigators
- Markus A Landolt, PhD, Principal investigator, University Children's Hospital, ZurichEdna Gruenblatt, PhD, Principal investigator, University of Zurich, Department of Child and Adolescent PsychiatryUeli Moehrlen, MD, Principal investigator, University Children's Hospital, ZurichTilo Burckhart, MD, Principal investigator, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04027374
- Sponsor's protocol ID
- BASEC 2019-00598
- Status last verified
- Nov 2023
- First submitted
- 16 Jul 2019
- Last updated
- 29 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 29 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Epigenetic Alterations in Stress Regulation Genes Among Newborns After Fetal Surgery for Myelomeningocele Repair: An Exploratory Study
- ClinicalTrials.gov ID
- NCT04027374
- Acronym / sponsor ID
- BASEC 2019-00598
- Conditions
- Meningomyelocele
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- University Children's Hospital, ZurichUniversity, hospital or other
- Collaborators
- University of Zurich, Psychiatric University Hospital, Zurich
- Study start
- 1 Jul 2019 (actual)
- Primary completion
- 30 Apr 2023 (actual)
- Study completion
- 31 Aug 2023 (actual)
- First posted
- 22 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Open spina bifida or myelomeningocele (MMC) is a devastating congenital defect of the central nervous system for which there is no cure. The etiology of MMC remains poorly understood. Primary failure of neural tube closure at the caudal neuropore in the embryonic period results in exposure of the developing spinal cord to the uterine environment. Without protective tissue coverage, secondary destruction of the exposed neural tissue by trauma or amniotic fluid may occur throughout gestation. In order to protect the spinal cord from this secondary destruction, a fetal surgical repair can be performed between gestational weeks 20 and 26.
From a psychological point of view fetal repair of MMC constitutes a highly stressful event both for the mother and the fetus. To date, however, stress of mothers and children in case of prenatal surgery for MMC repair has never been studied. It is therefore unclear, if and to what extend the procedure and its consequences are associated with stress, and if there are short- or longer-term consequences.
The aims of this study are threefold:
- Do newborns after fetal surgery for MMC show epigenetic alterations in genes that are involved in stress regulation?
- With which medical and psychosocial variables are epigenetic alterations associated?
- At age 3 months, do infants after fetal surgery have a more difficult temperament compared to controls?
Detailed description
BACKGROUND AND AIMS:
Open spina bifida or myelomeningocele (MMC) is a devastating congenital defect of the central nervous system for which there is no cure. The etiology of MMC remains poorly understood. Primary failure of neural tube closure at the caudal neuropore in the embryonic period results in exposure of the developing spinal cord to the uterine environment. Without protective tissue coverage, secondary destruction of the exposed neural tissue by trauma or amniotic fluid may occur throughout gestation. In order to protect the spinal cord from this secondary destruction, a fetal surgical repair can be performed between gestational weeks 20 and 26.
From a psychological point of view fetal repair of MMC constitutes a highly stressful event both for the mother and the fetus. To date, however, stress of mothers and children in case of prenatal surgery for MMC repair has never been studied. It is therefore unclear, if and to what extend the procedure and its consequences are associated with stress, and if there are short- or longer-term consequences.
The aims of this study are threefold:
- Do newborns after fetal surgery for MMC show epigenetic alterations in genes that are involved in stress regulation?
- With which medical and psychosocial variables are epigenetic alterations associated?
- At age 3 months, do infants after fetal surgery have a more difficult temperament compared to controls?
METHODS:
Sample: The study will include newborns after fetal surgery for MMC at the University Hospital Zurich and two control groups. One including healthy newborns and another including newborns after prenatal exposure to synthetic glucocorticoids (sGC) in pregnancy. Each group shall include n=30 newborns (i.e. total number of study participants: n=90).
Recruitment and Procedures: Recruitment will take place at the University Children's Hospital and the University Hospital Zürich and will be continued until the required sample size is reached. For every MMC-patient, secondary recruitment of a control child for group 2 and 3 will be performed (matched for child sex). Parents of all study groups will be approached by the responsible study staff after checking for inclusion and exclusion criteria. They will be informed orally about the study and the study information letter (see encl.) will be provided. Parents will be contacted again after >24h face to face or by phone by study staff to answer any questions, if necessary. If the parents agree to participate in the study, they will provide the signed written informed consent form (see encl.). After inclusion in the study, the parents will be contacted again in hospital by study staff around 24-36 hours after birth to re-explain the collection of the saliva samples. The saliva samples will then be collected between 24 and 72h postpartum. Six weeks and 3 months post-partum, the parents will receive the study questionnaires by mail and they will be asked to complete and return them within 1 week. If the questionnaires are not received after 10 days, study staff will contact the parents by phone for a gentle reminder. Parents are not financially compensated for taking part in the study.
Collected data:
-) DNA and RNA sample collection from the child will take place between 24 and 72 hours of life during hospitalization by trained research project staff. In order to obtain DNA and RNA, saliva will be collected using special sponge devices designed for use with infants who cannot spit independently.
For DNA, 2x ORAcollect for pediatrics (OC-175; DNA Genotek Inc) will be used to collect saliva in order to obtain enough DNA sample.
For RNA, 2x saliva collection devices for pediatrics (CP-190; DNA Genotek Inc) will be used to collect saliva in order to obtain enough RNA sample from the newborns.
- Medical data: a) Child: Gestational age at birth; gender; birth length and percentile; birth weight and percentile; head circumference at birth and percentile; Apgar score; umbilical artery ph and lactate; meconium-stained amniotic fluid; Gestational age at fetal surgery; time and length of fetal surgery; positioning of the fetus necessary; transfer to neonatology (group 2 and 3). b) Mother: Maternal age; parity; gestational age at glucocorticoid treatment; treatment of preterm labour; medications during pregnancy; surgery and perinatal variables; history in terms of smoking, alcohol, nicotine, marihuana, other illicit drugs; Indication for ECS (group 2 and 3).
- Psychosocial data: The following variables shall be assessed from mothers by standardized and validated questionnaires: country of birth (parents, grandparents); Socio-economic status, maternal and parental education; current job situation (no, part-time, full-time); maternal and paternal trauma history (Childhood Trauma Questionnaire - Short Form from Bernstein \& Fink, 1998; Karos et al. 2014); significant life events during the pregnancy (Life Event Scale from Landolt \& Vollrath, 1998); maternal and paternal subjective stress during pregnancy (Perceived Stress Scale PSS-10 from Cohen, Kamarck, \& Mermelstein (1983) and Klein et al. (2016); maternal and paternal mental health both retrospectively during pregnancy and currently at the assessment points after birth: anxiety and depression by means of two modules of the Patient Health Questionnaire PHQ from Spitzer, Kroenke, \& Williams (1999); posttraumatic stress disorder by means of the International Trauma Questionnaire ITQ (Cloitre et al., 2018) and the infant's temperament by means of the Infant Behaviour Questionnaire IBQ - Very Short Form by Rothbart (1981). All measures are standardized and available in validated German versions.
Statistical Analyses: Aim 1 will be examined with ANCOVAs to compare total methylation / gene-expression (mRNA level) for the studied gene regions across the 3 groups. The correlation between methylation levels and gene-expression will be investigated, expecting that hypermethylation induces reduced gene-expression and vice versa.
Aim 2 will be examined by (partial) correlational analyses between predictor variables and total methylation. If requirements are met, multivariate analyses will be performed.
Aim 3 will be examined with ANCOVAs comparing IBQ-scores across the three groups.
Data will not be transformed before analysis. If the data doesn't meet the requirements for the selected statistical tests, then modified tests (e.g. one-way testing) or appropriate tests (e.g. non-parametric methods) will be used.
Statistical analysis will be performed either with the program Statistical Package for Social Sciences (SPSS, Version 25) or the statistical program R. Statistical significance will be set to a significance level of α= <.05.
Sample size: According to a power-analysis calculation with the program G*Power 3.1 (Faul, Erdfelder, Buchner \& Lang, 2009), the required sample size for an ANCOVA with 3 groups, an effect size of d=0.4 (small effect) and a power of .90 is n=84.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Fetal surgery group | – | Procedure: Fetal surgery for MMC repairNewborns after successful fetal surgery for MMC, delivered by elective c-section at weeks 35;0 - 37;0. |
| Glucocorticoid control group | – | –Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by elective c-section between 35;0 - 40;0 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure. |
| Healthy controls | – | –Healthy newborns, uncomplicated pregnancy, delivered at term by elective c-section between 36;0 - 39;0 weeks. Matched for child sex with group 1. |
Who may qualify
- Ages
- 2 days to 3 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- The study will include newborns after fetal surgery for MMC at the University Hospital Zurich and two control groups. One including healthy newborns and another including newborns after prenatal exposure to synthetic glucocorticoids (sGC) in pregnancy. Each group shall include n=30 newborns (i.e. total number of study participants: n=90). In the following paragraph you can find a detailed description of the groups as well as the inclusion and exclusion criteria for all groups.
Key inclusion criteria (3 listed)
- Group 1: Newborns after successful fetal surgery for MMC, delivered by ECS (elective c-section) at weeks 350 - 370.
- Group 2: Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by ECS between 350 - 400 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure.
- Group 3: Healthy newborns, uncomplicated pregnancy, delivered at term by ECS between 360 - 390 weeks (healthy controls). Matched for child sex with group 1.
Key exclusion criteria (8 listed)
- Multiple pregnancies
- Apgar 5 min <=7, or significant postpartal health problems such as respiratory distress syndrome
- ph<7.15
- General anaesthesia for ECS
- Insufficient knowledge of German or English by the mother
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fetal surgery for MMC repairFetal surgery for MMC repair | Procedure or surgery | Fetal surgery group |
Primary outcome
Methylation status at NRC3C1 and the FKBP5 gene
Time frame: Day 2 - Day 3
Saliva DNA will be isolated using prepIT.L2P following manufacturer's protocol (PT-L2P; DNA Genotek Inc.). DNA concentration, A260/A280 and A260/A230 ratios for integrity and quality will be measured using the NanoDrop spectrophotometer (ThermoFisher, Switzerland). DNA methylation specific analysis for each selected gene (NR3C1 and FKBP5) will be conducted using the EpiTect Methyl II PCR assays (Qiagen) following the manufacturer's protocol.
1 secondary outcome
Patient Health Questionnaire (PHQ)
Time frame: Week 6 and month 3
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Nov 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Meningomyelocele
Recruiting
Transcutaneous Spinal Stimulation for Children and Youth With Spina Bifida
Myelomeningocele, Spina Bifida
Active, not recruitingPhase 1
Patch vs. No Patch Fetoscopic Meningomyelocele Repair Study
Neural Tube Defects
Recruiting
Autologous Human Umbilical Cord Tissue Patch for Postnatal Closure of Open Neural Tube Defects
Spina Bifida
Recruiting
tSCS in Children With Spina Bifida
Spina Bifida, Myelomeningocele
Active, not recruiting
Fetoscopic NEOX Cord 1K® Spina Bifida Repair
Spina Bifida, Myelomeningocele
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Markus A Landolt, PhD principal investigator
University Children's Hospital, Zurich
Edna Gruenblatt, PhD principal investigator
University of Zurich, Department of Child and Adolescent Psychiatry
Ueli Moehrlen, MD principal investigator
University Children's Hospital, Zurich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Meningomyelocele, run by University Children's Hospital, Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Methylation status at NRC3C1 and the FKBP5 gene (time frame: Day 2 - Day 3). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Nov 2023.